Mauro Schechter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Science s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation
Last-minute vaccine dosing changes that could gamble away proven COVID-19 protection and undermine public trust. Controversial approvals without any efficacy data. Vaccinemakers at odds with countries hosting their clinical trials. The COVID-19 vaccine landscape keeps changing almost daily, simultaneously raising hopes and triggering confusion and scientific debates. “It s crazy,” says vaccine researcher John Moore of Weill Cornell Medicine. “Every morning, it s just, ‘What s going on?’”
Over the past few weeks, COVID-19 vaccines developed in the United Kingdom, China, and India moved toward widespread rollout, offering new weapons in the face of fast-spreading viral variants that threaten to deepen the crisis (see p. 108). But many came with controversies, and U.K. regulators sparked a debate when they endorsed a sharp departure from the expected dosing schedule ....

United States , Rio De Janeiro , Estado Do Rio , United Kingdom , United Arab Emirates , Moncef Slaoui , John Moore , Paul Offit , Mauro Schechter , Peter Marks , Oxford Adrian Hill , Vineeta Bal , Heising Simons Foundation , University Of Oxford , University Of Rio De Janeiro , Drug Administration , Doctor Association United Kingdom , British Society For Immunology , Central Drugs Standard Control Organisation , Sinopharm China National Biotec Group , Regulatory Agency , College City , Pulitzer Center , India National Institute Of Immunology , Weill Cornell , Natalie Dean ,